For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Corcept Therapeutics Inc’s stock clocked out at $62.29, up 5.52% from its previous closing price of $59.03. In other words, the price has increased by $5.52 from its previous closing price. On the day, 1.06 million shares were traded. CORT stock price reached its highest trading level at $62.98 during the session, while it also had its lowest trading level at $58.28.
Ratios:
To gain a deeper understanding of CORT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 45.77. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 10 ’25 when Swisher Daniel N JR sold 2,200 shares for $50.54 per share. The transaction valued at 111,188 led to the insider holds 0 shares of the business.
Swisher Daniel N JR bought 2,200 shares of CORT for $111,188 on Jan 10 ’25. On Jan 02 ’25, another insider, Maduck Sean, who serves as the insider of the company, sold 20,000 shares for $50.39 each. As a result, the insider received 1,007,800 and left with 85,318 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 6526434816 and an Enterprise Value of 6152898048. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.54, and their Forward P/E ratio for the next fiscal year is 32.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.38 while its Price-to-Book (P/B) ratio in mrq is 10.21. Its current Enterprise Value per Revenue stands at 9.789 whereas that against EBITDA is 42.703.
Stock Price History:
The Beta on a monthly basis for CORT is 0.57, which has changed by 1.7253001 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $62.22, while it has fallen to a 52-week low of $20.84. The 50-Day Moving Average of the stock is 12.45%, while the 200-Day Moving Average is calculated to be 56.11%.
Shares Statistics:
It appears that CORT traded 921.32K shares on average per day over the past three months and 809460 shares per day over the past ten days. A total of 104.70M shares are outstanding, with a floating share count of 90.25M. Insiders hold about 13.87% of the company’s shares, while institutions hold 82.25% stake in the company. Shares short for CORT as of 1735603200 were 15958163 with a Short Ratio of 17.32, compared to 1732838400 on 17051615. Therefore, it implies a Short% of Shares Outstanding of 15958163 and a Short% of Float of 21.39.
Earnings Estimates
Corcept Therapeutics Inc (CORT) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.31, with high estimates of $0.36 and low estimates of $0.25.
Analysts are recommending an EPS of between $1.44 and $1.3 for the fiscal current year, implying an average EPS of $1.35. EPS for the following year is $1.67, with 3.0 analysts recommending between $1.9 and $1.36.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $198.88M. It ranges from a high estimate of $207.42M to a low estimate of $192.8M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $135.41MFor the next quarter, 4 analysts are estimating revenue of $189.07M. There is a high estimate of $207.8M for the next quarter, whereas the lowest estimate is $169M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $700.57M, while the lowest revenue estimate was $686M, resulting in an average revenue estimate of $692.04M. In the same quarter a year ago, actual revenue was $482.38MBased on 4 analysts’ estimates, the company’s revenue will be $812.35M in the next fiscal year. The high estimate is $876.4M and the low estimate is $759.9M.
